INTRODUCTION
Several concerns have been raised by recently published meta-analyses (2014) (2015) comparing coronary artery bypass surgery (CABG) with percutaneous coronary intervention (PCI) in patients with type 2 diabetes mellitus (T2DM). For example, Bangalore et al. [1] recently published the results of a network meta-analysis, which led them to conclude that mortality following CABG was similar to that following PCI in patients with diabetes mellitus. However, Toeg et al. found that conclusion to be highly problematic and pointed to the results of their own meta-analysis [2] ; in response, Bangalore et al. [3] defended their results and pointed out certain limitations of Toeg et al.'s meta-analysis. Aside from this particular controversial issue, other meta-analyses in this field have also reached divergent conclusions [4, 5] . Given this controversy as well as recent developments in interventional cardiology and the recent introduction of new guidelines for antiplatelet therapies (with new participants being treated based on those recent guidelines), in the work reported in the present paper, we aimed to systematically re-assess the important issue of whether PCI should be recommended over CABG or vice versa using data from the most recent cohort of T2DM patients (2015-2017).
METHODS

Data Sources
Only an electronic search was carried out (no manual search). The following databases were searched: MEDLINE (including PubMed); Cochrane Database; EMBASE database; Google Scholar; official websites of several common cardiology journals.
Search Terms
The main search terms were 'diabetes mellitus,' 'coronary artery bypass surgery,' and 'percutaneous coronary intervention.' Other terms searched for included 'coronary angioplasty,' 'cardiac surgery,' 'type 2 diabetes mellitus,' and abbreviations such as CABG and PCI.
Outcomes
The following outcomes (Table 1) were compared: mortality; myocardial infarction (MI); repeat revascularization (RR); stroke; major adverse events (MAEs), which refers to major adverse cardiac events and cerebrovascular events (including death, MI, RR, and/or stroke).
Follow-up Periods
The follow-up period varied from 1 to 5 years. However, most of the studies had a follow-up period of more than 3 years, as shown in Table 1 .
Data Extraction and Review
The reviewers who were involved in the data extraction process were Xia Dai, Zu-chun Luo, Lu Zhai, Wen-piao Zhao, and Feng Huang. Data extracted included: type of study; total number of patients treated with CABG; total number of patients treated with PCI; year of publication (2015-2017); diseases of the participants; baseline features; outcomes and corresponding numbers of events; follow-up periods. Any disagreement was resolved by consensus.
The trials were assessed for risk of bias with reference to the Cochrane Collaboration [6] . Approximate grades of between A and E were allotted to the trials depending on their risk of bias; A corresponded to a low risk of bias, whereas E indicated a high risk.
Statistical Analysis
The software used for statistical analysis was RevMan version 5.3. The analytical parameters of most interest were the odds ratios (OR) with 95% confidence intervals (CIs). Heterogeneity was assessed using two tests [6] : (a) Q statistic test: P \ 0.05 was considered to indicate a statistically significant result (b) I 2 statistic test: the higher the percentage value of I 2 , the greater the heterogeneity In terms of the statistical model applied, a fixed effects model was used if I 2 was \ 50%, and a random effects model was used if I 2 was [ 50%. Sensitivity analysis was carried out using an exclusion method whereby multiple analyses were performed, with a different trial/observational study excluded in each analysis. Publication bias was assessed by observing the shape of the funnel plot.
Compliance with Ethics Guidelines
This meta-analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Figure 1 presents the study selection procedure for this analysis (the PRISMA guideline was followed [7] ). Eight studies were ultimately included in the analysis [8] [9] [10] [11] [12] [13] [14] [15] .
RESULTS
Search Results and General and Baseline Features
A total of 13,114 patients with T2DM were included in this meta-analysis (5502 patients Li et al. [14] Mortality, MI, RR, stroke, MAEs T2DM and CAD 5
Ramanathan et al. [15] Mortality, MI, RR, stroke, MAEs T2DM and ACS 5
MAEs major adverse events, MI myocardial infarction, RR repeat revascularization, T2DM type 2 diabetes mellitus, CAD coronary artery disease, NSTEMI non-ST segment elevation myocardial infarction, MVD multi-vessel coronary disease, LMCAD left main coronary artery disease, ACS acute coronary syndrome were treated with CABG and 7612 patients were treated with PCI), as shown in Table 2 . The baseline characteristics of the patients are presented in Table 3 .
Main Results of this Analysis
This analysis-which only included trials and observational studies published after the year 2014-showed that during follow-up periods RCT randomized controlled trial, OS observational study, CABG coronary artery bypass surgery, PCI percutaneous coronary intervention C coronary artery bypass surgery, P percutaneous coronary intervention, HTN hypertension, Ds dyslipidemia, Cs current smokers, EES everolimus-eluting stents, DES drug-eluting stents, DES* drug-eluting stents with the inclusion of a small percentage of bare metal stents ranging from 1 to 5 years, mortality in T2DM patients treated with CABG was not significantly different from that in T2DM patients treated with PCI (OR 0.90, 95% CI 0.61-1.31; P = 0.57, as shown in Fig. 2 ). Stroke rates were also similar in the two groups (OR 1.24, 95% CI 0.78-1.99; P = 0.36). However, the rate of MAEs was significantly higher in the PCI group (OR 0.63, 95% CI 0.48-0.82; P = 0.0006, as shown in Fig. 2 ). The rates of cardiac death in the two groups were not significantly different (OR 1.00, 95% CI 0.78-1.30; P = 0.98). However, the rates of repeat revascularization and MI were significantly more favorable with CABG than with PCI (OR 0.27, 95% CI 0.24-0.30; P = 0.00001 and OR 0.40, 95% CI 0.35-0.47; P = 0.00001, respectively, as shown in Fig. 3) .
When a sensitivity analysis was carried out, the results showed that the findings of this analysis were not excessively influenced by any of the studies. There was also little evidence of publication bias.
DISCUSSION
Recently, several issues have been raised as a result of comparisons of the adverse outcomes of CABG with those of PCI in patients with T2DM [1] . Mortality was reported to be similar in PCI and CABG patients with T2DM, which was seen as a problematic conclusion. Therefore, in the present analysis, we recompared the outcomes of PCI and CABG using data from recently published studies of T2DM patients in order to check this conclusion.
The results of the present analysis show that during follow-up periods ranging from 1 to 5 years, all-cause mortality and the rate of cardiac death in T2DM patients treated with CABG were not significantly different from those in T2DM patients treated with PCI. However, the rate of MAEs (including MI and RR) was significantly higher with PCI. The difference in stroke rate between the groups was not statistically significant.
Patients with T2DM are more at risk of instent restenosis following PCI, even during a medium-term rather than long-term follow-up period, which contributes to the significantly higher MAE rate compared to T2DM patients treated with CABG. The incidence of both occlusive and nonocclusive re-stenosis has been shown to be higher in uncontrolled DM patients. Even if diabetes mellitus is independently associated with adverse outcomes following PCI, insulin treatment and the severity of this chronic disease may be other causes of adverse outcomes.
This analysis of newly published data supports the results obtained by Bangalore et al. [1] , suggesting that their conclusion is not ''problematic.'' Even though they carried out a network meta-analysis, which performed indirect comparisons, the results of the present analysis-which involved direct comparisons-did not show any significant difference from their results.
Fig. 3 Comparison of adverse outcomes in CABG versus PCI patients with T2DM (part II)
A recent publication in Scientific Reports [16] also presented similar results to the current analysis, even though it did not specifically include patients with T2DM. No difference in mortality between patients treated with an everolimus-eluting stent (EES) and those treated with CABG was observed, whereas EES was associated with a significantly higher rate of major adverse cardiovascular events than CABG. In addition, in a study focusing on patients with multi-vessel coronary disease and severe left ventricular systolic dysfunction, long-term mortality in the PCI and CABG groups was comparable, whereas the PCI group was associated with significantly higher rates of MI and repeat revascularization [17] .
Results of other studies in which a significantly higher mortality was associated with PCI in T2DM patients than with CABG in T2DM patients could be due to the use of insulin treatment, as previously stated [18] .
Nevertheless, the selection of patients for CABG or PCI should be partly based on their SYNTAX scores, especially for patients with T2DM, since they may have other comorbidities. Even though CABG should be considered the optimal revascularization strategy, PCI could be more applicable to a few patients according to their SYNTAX scores. The application of the SYNTAX score in interventional cardiology should be encouraged [19] .
Limitations
This study has a number of limitations. First, the total number of patients was not high enough to reach a definitive conclusion. Second, patient data from randomized trials and observational studies were combined and analyzed. Third, the follow-up periods varied between studies. Fourth, the diseases (e.g., left main coronary artery disease, multi-vessel disease, diabetic nephropathy) suffered by the participants varied. Finally, the data were adjusted to represent less heterogeneity.
CONCLUSIONS
During follow-up periods of 1-5 years, mortality in T2DM patients treated with CABG did not differ significantly from mortality in T2DM patients treated with PCI. However, the rate of other major adverse events was significantly higher in the CABG group compared to the PCI group. 2016GXNSFAA380002). No funding was received for the publication of this article. The article processing charges were funded by the authors.
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